Milena Krajnović
University of Belgrade
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Milena Krajnović.
Clinical and Translational Science | 2014
Milena Krajnović; Mr.Sci. Maja Peruničić Jovanović M.D.; Biljana Mihaljevic; Boško Anđelić; Olivera Tarabar; Slavica Knežević-Ušaj; Koviljka Krtolica
In this study, methylation‐specific polymerase chain reaction was used to investigate the potential prognostic significance of the methylation status of p15, p16, MGMT, and DAPK genes in 51 specimens of diffuse large B‐cell lymphoma (DLBCL). Hypermethylation of p15 gene was significantly more prevalent in patients without relapse (p = 0.001) and there was a trend toward more frequent presence of p15 methylation in patients without death outcome within 5‐year follow‐up period (p = 0.086) Also, there was a trend toward accumulation of p15 methylation with favorable clinicopathological parameters including: age ≤ 60 years (p = 0.091), normal levels of lactate dehydrogenase (p = 0.090), Eastern Cooperative Oncology Group performance status < 2 (p = 0.095), and low/intermediate low International Prognostic Index (p = 0.076). In the female group and group of the patients without bulky tumor mass, treated with chemotherapeutic regimens including rituximab, methylation of p15 was significantly related to longer overall survival (p = 0.036 and 0.027, respectively). Our results suggest that promoter methylation of p15 gene could have prognostic value in DLBCL patients treated with rituximab when used in combination with gender and tumor size.
Central European Journal of Biology | 2014
Radoslav Davidovic; Ana M. Božović; Vesna Mandusic; Milena Krajnović
Methylation-specific PCR (MSP) is still the method of choice for a single gene methylation study. The proper design of the primer pairs is a prerequisite for obtaining reliable PCR results. Despite numerous protocols describing the rules for MSP primer design, none of them provide a comprehensive approach to the problem. Our aim was to depict a workflow for the primer design that is concise and easy to follow. In order to achieve this goal, adequate tools for promoter sequence retrieval, MSP primer design and subsequent in silico analysis are presented and discussed. Furthermore, a few instructive examples regarding a good versus a poor primer design are provided. Finally, primer design is demonstrated according to the proposed workflow. This article aims to provide researchers, interested in a single gene methylation studies, with useful information regarding successful primer design.
Pathology Research and Practice | 2016
Milena Krajnović; Bojana M. Marković; Slavica Knežević-Ušaj; Ivan Nikolić; Maja Stanojevic; Valentina Nikolic; Marina Siljic; Snežana Jovanović Ćupić; Bogomir Dimitrijević
In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p=0.030), a more frequent appearance of local recurrences and distant metastasis (p=0.003), and shorter overall survival (p=0.001) compared to all others. On the contrary, patients with GGT>GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p=0.017). Moreover, the presence of GGT>GCT mutation was associated with low VEGF and Ki67 expression (p=0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response.
Clinica Chimica Acta | 2006
Vesna Ivanović; Miroslav Demajo; Koviljka Krtolica; Milena Krajnović; Miroslav Konstantinović; Vladimir Baltić; Gordana Prtenjak; Bratislav Stojiljković; Milan Breberina; Zora Nes˘ković-Konstantinović; Dragica Nikolic-Vukosavljevic; Bogomir Dimitrijević
World Journal of Gastroenterology | 2007
Koviljka Krtolica; Milena Krajnović; Slavica Usaj-Knezevic; Dragan Babic; Dusan Jovanovic; Bogomir Dimitrijević
Medical Oncology | 2013
Milena Krajnović; Milica Radojkovic; Radoslav Davidovic; Bogomir Dimitrijević; Koviljka Krtolica
Molecular Diagnosis & Therapy | 2016
Nina Petrovic; Radoslav Davidovic; Snezana Jovanovic-Cupic; Milena Krajnović; Silvana Lukić; Milan Petrovic; Jelena Roganović
Medical Oncology | 2012
Nada Kraguljac Kurtovic; Milena Krajnović; Andrija Bogdanovic; Nada Suvajdžić; Jelica Jovanovic; Bogomir Dimitrijević; Milica Colovic; Koviljka Krtolica
Leukemia Research | 2007
Gordana Bogdanović; Vladimir Jurisic; Nada Kraguljac; Jasminka Mrdjanovic; Dimitar Jakimov; Koviljka Krtolica; Milena Krajnović; Zvonko Magic; Bratislav Stojiljković; Ljiljana Andrijević; Tatjana Srdic; Mirjana Baltić; Stevan Popovic
Medical Oncology | 2013
Radoslav Davidovic; Jelena Sopta; Vesna Mandusic; Milena Krajnović; Maja Stanojevic; Goran Tulic; Bogomir Dimitrijević